Figure 2
JAK2V617F mice develop a myeloproliferative disease. (A) Time course of blood parameters of JAK2V617F and control mice showing significantly increased platelets, hematocrit, and hemoglobin, and moderately elevated white blood cell counts (JAK2V617F, JAK2F/+Mx1Cre+; controls, JAK2+/+Mx1Cre+). Data are mean ± SEM. (B) Hematoxylin and eosin staining of BM with megakaryocytic hyperplasia with increased clustering and hyperlobated nuclei. (C) Myeloproliferative phenotype is transplantable. Histograms show blood counts of recipient mice 12 weeks after transplantation of 1 × 106 BM cells from either JAK2V617F or control mice. *P < .05. **P < .01. NS indicates not significant. Data are mean ± SEM.

JAK2V617F mice develop a myeloproliferative disease. (A) Time course of blood parameters of JAK2V617F and control mice showing significantly increased platelets, hematocrit, and hemoglobin, and moderately elevated white blood cell counts (JAK2V617F, JAK2F/+Mx1Cre+; controls, JAK2+/+Mx1Cre+). Data are mean ± SEM. (B) Hematoxylin and eosin staining of BM with megakaryocytic hyperplasia with increased clustering and hyperlobated nuclei. (C) Myeloproliferative phenotype is transplantable. Histograms show blood counts of recipient mice 12 weeks after transplantation of 1 × 106 BM cells from either JAK2V617F or control mice. *P < .05. **P < .01. NS indicates not significant. Data are mean ± SEM.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal